STEVENSON, Md., Sept. 09, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Colorado on behalf of purchasers of Chipotle Mexican Grill, Inc. (NYSE:CMG) (“Chipotle” or the “Company”) securities during the period between February 5, 2016, and July 19, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until September 18, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Chipotle securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Chipotle’s purported improvements in its restaurants’ food safety policies were inadequate, its quality controls were still not in compliance with applicable consumer and workplace safety regulations, and Chipotle’s quality controls remained inadequate to safeguard consumer and employee health.
According to the complaint, following July 18, 2017 articles reporting that Chipotle had closed a restaurant in Sterling, Virginia due to a suspected norovirus outbreak, and a July 20, 2017 article disclosing that the number of reports of illnesses continued to rise, the value of Chipotle shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Chipotle securities purchased on or after February 5, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Apple Turns 50: From Garage Startup to AI Crossroads
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



